Individualized Cancer Therapy Demonstrates Safety and Sustained Immune Responses

Individualized Cancer Therapy Demonstrates Safety and Sustained Immune Responses

Publication date: Aug 07, 2024

The researchers are also seeking to further advance the study of the INT in non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and cutaneous squamous cell carcinoma. Such immunotherapies have become increasingly important in treating cancer and may be used alongside INTs to further increase the immune system’s ability to stage a long-lasting response to cancer. However, success has been limited due to the technological challenge of engineering therapies that provide specific enough -training” to the immune system to identify a given patient’s neoantigens. -We showed that this INT was able to generate new immune responses against neoantigens, and it appeared that those immune responses were maintained at later time points. The FDA granted a breakthrough therapy designation to the study of mRNA-4157 (V940) with pembrolizumab for melanoma treatment, which can help expedite the development and review of the treatment. The potential for a precise, durable immune response is one of the most exciting aspects of therapies like this one. -While it may sound like science fiction, we’ve shown that we can develop an individualized neoantigen therapy by leveraging the specific characteristics of a given patient’s tumor and cell-type.

Concepts Keywords
American Brigham
Cancer Care
Harvard General
Nct03313778 Immune
Teaching Individualized
Mass
Merck
Mrna
Neoantigens
Patients
System
Therapies
Therapy
Treatment
V940

Semantics

Type Source Name
disease MESH renal cell carcinoma
pathway KEGG Renal cell carcinoma
disease MESH carcinoma
disease MESH squamous cell carcinoma
pathway KEGG Melanoma
disease MESH melanoma
disease MESH Cancer
drug DRUGBANK Pembrolizumab
disease MESH causes
disease MESH lost to follow-up
pathway KEGG Non-small cell lung cancer
disease MESH non-small cell lung cancer
drug DRUGBANK Spinosad
disease MESH lung cancer
pathway REACTOME Immune System

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *